The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2024 | HERTHENA-Lung02: exploring patritumab deruxtecan in NSCLC
Benjamin Besse, MD, PhD, Gustave Roussy, Villejuif, France, discusses the ongoing investigation of patritumab deruxtecan, an anti-HER3 antibody-drug conjugate (ADC), in non-small cell lung cancer (NSCLC). The ADC is compared against platinum-based chemotherapy, the approved standard regimen in the Phase III HERTHENA-Lung02 trial (NCT05338970). While HER3 expression cannot be assessed via liquid biopsy, the study aims to explore alternative treatment options for patients with NSCLC, highlighting the potential of patritumab deruxtecan in reshaping future therapeutic strategies. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
